A phase II clinical trial to assess the safety of clonidine in acute organophosphorus pesticide poisoning.
BACKGROUND
An estimated 2-3 million people are acutely poisoned by organophosphorus pesticides each year, mostly in the developing world. There is a pressing need for new affordable antidotes and clonidine has been shown to be effective in animal studies. Our aim was to determine the safety of clonidine given as an antidote in adult patients presenting with signs or symptoms of acute organophosphate ingestion.


METHODS
This study was a dose finding, open-label, multicentre, phase II trial. Forty eight patients with acute organophosphate poisoning were randomized to receive either clonidine or placebo: Four to receive placebo and twelve to receive clonidine at each dose level. The first dose level was an initial loading dose of 0.15 mg followed by an infusion of 0.5 mg of clonidine over 24 hours. The initial loading dose was increased to 0.3 mg, 0.45 and 0.6 mg. at all dosing levels however the subsequent infusion remained at 0.5 mg of clonidine over 24 hours.


RESULTS
The baseline characteristics of both groups were similar. The trial was stopped after completion of the 3rd dosing level. At the 1st and 2nd dosing level there were no reported adverse drug reactions. At the 3rd dosing level 5 patients (42%) developed significant hypotension during clonidine treatment that responded to intravenous fluids. There were no statistical differences in ventilation rate, pre and post GCS, and mortality rates over all levels.


CONCLUSIONS
Our findings suggest use of moderate doses of clonidine in acute organophosphate poisoning can be used without causing frequent clinical problems but that higher doses are associated with a high incidence of hypotension requiring intervention. Further studies are needed to study the efficacy of clonidine as an antidote in organophosphate poisoning.
Perera
Polwattage M S
PM
South Asian Clinical Toxicology Research Collaboration, Faculty of Medicine, University of Peradeniya, Sri Lanka. mark@sactrc.org
Jayamanna
Shaluka F
SF
Hettiarachchi
Raja
R
Abeysinghe
Chandana
C
Karunatilake
Harindra
H
Dawson
Andrew H
AH
Buckley
Nick A
NA
D000208:Acute Disease; D000328:Adult; D000931:Antidotes / Q000009:adverse effects*; D003000:Clonidine / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D062025:Organophosphate Poisoning; D010575:Pesticides / Q000506:poisoning*
D000931:Antidotes; D010575:Pesticides; D003000:Clonidine
Clin Exp Pharmacol Physiol. 2005 Nov;32(11):999-1005
16405459
QJM. 2002 May;95(5):275-83
11978898
J Toxicol Clin Toxicol. 2002;40(2):145-55
12126186
J Toxicol Clin Toxicol. 2002;40(5):551-5
12215049
Paediatr Anaesth. 1999;9(3):187-202
10320597
Res Commun Chem Pathol Pharmacol. 1992 Jan;75(1):85-98
1352646
QJM. 2000 Nov;93(11):715-31
11077028
JAMA. 1977 Oct 31;238(18):1930-2
578552
Br J Psychiatry. 2006 Sep;189:201-3
16946353
J Pharmacol Exp Ther. 1982 Sep;222(3):595-9
6286926
J Pharmacol Exp Ther. 1986 Oct;239(1):43-7
3761196
Br J Pharmacol Chemother. 1953 Dec;8(4):466-75
13115640
BMC Public Health. 2007 Dec 21;7:357
18154668
Toxicol Appl Pharmacol. 1995 Jun;132(2):343-5
7785062
J Toxicol Clin Toxicol. 2004;42(4):343-7
15461241
Toxicol Lett. 1988 Sep;42(3):291-9
3176058
QJM. 2006 Aug;99(8):513-22
16861715
J Biomed Sci. 1999 Mar-Apr;6(2):86-96
10087439
Neurotoxicol Teratol. 1989 Jan-Feb;11(1):39-44
2725439
Pharmacol Biochem Behav. 1988 Feb;29(2):309-13
3362926
DICP. 1989 Jun;23(6):465-6
2741480
Life Sci. 1986 Dec 1;39(22):2097-102
3784771
Lancet. 2005 Oct 22-28;366(9495):1452-9
16243090
Lancet. 2008 Feb 16;371(9612):597-607
17706760